Targets › KIR2DL3
1 program from 1 company in 1 trial: 1 Phase 2; Oncology.
Receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). Inhibits the activity of NK cells thus preventing cell lysis. (UniProt, P43628)
Open in Phaseline: the race on KIR2DL3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Dana-Farber Cancer Institute | Lirilumab Killer cell immunoglobulin-like receptor 2DL1 inhibitor; Killer cell immunoglobulin-like receptor 2DL2 inhibitor; Killer cell immunoglobulin-like receptor 2DL3 inhibitor | KIR2DL1, KIR2DL3 | Phase 2 | Squamous Cell Carcinoma of the Head and Neck | – |
Squamous Cell Carcinoma of the Head and Neck (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.